Chemokine Therapeutics Initiating Coverage by Investrend Research Provider Fundamental Research.NEW YORK -- (Investrend Research Syndicate) Fundamental Research Corp analyst Amit Bandekar has initiated coverage of Chemokine chemokine /che·mo·kine/ (ke´mo-kin) any of a group of low molecular weight cytokines identified on the basis of their ability to induce chemotaxis or chemokinesis in leukocytes (or in particular populations of leukocytes) in inflammation. Therapeutics Corp (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension : CTI; OTCBB OTCBB See OTC Bulletin Board (OTCBB). : CHKT) in a report dated June 24, 2005. A summary of the report follows below; the full 30-Page update is available free for a limited time at http://www.fundamentalresearchcorp.com and http://www.investrendresearch.com. According to the report, CTI has an experienced management team with diverse skill sets. It has also entered into collaborations with reputed firms such as PPD (1) (Parallel Presence Detect) The method used by earlier SIMM memory modules to communicate their capacity to the computer. A binary number coming from a parallel set of pins was read by the system, with each pin representing one bit. Contrast with SPD. , Inc. and Procter and Gamble (NYSE NYSE See: New York Stock Exchange : PG) Pharmaceuticals for developing key molecules. The analyst believes that the technology and processes used by CTI for R&D are well established, leading to faster identification and selection of receptor sites. The company has 8 patents with 15 pending including a unique and diversified pipeline in attractive therapeutic areas. The analyst is of the opinion that revenue potential will increase substantially as the company moves from a Phase I company to a Phase II for its oncology candidate and other clinical trials. The report uses three valuation methods to conclude that CTI shares are undervalued Undervalued A stock or other security that is trading below its true value. Notes: The difficulty is knowing what the "true" value actually is. Analysts will usually recommend an undervalued stock with a strong buy rating. . For example, according to the analyst, the average biotech with Phase I drugs is typically valued at $159 million in market cap versus only $35 million for CTI. The analyst also notes five key risk factors including: Product Failure - the drug candidates may fail at any stage during the development process, Cash Flow/Financing - if CTI is not able to secure financing before revenues are generated, it will not be able to continue operating beyond two years, Regulatory - the company may face regulatory delays in product approvals (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) or other stages. Dilution - the company has been covering basic expenses by issuing equity which may dilute existing shareholders, and Competition - the initial successes of the drug candidates may attract competitors who seek to develop similar classes of drugs. Fundamental Research is a research provider to Investrend Research and subscribes to the "Standards For Independent Research Providers" at http://www.firstresearchconsortium.com. Fees of less than $25,000 have been paid by the company to FRC FRC abbr. functional residual capacity FRC see functional residual capacity. . FRC and Investrend Research take steps to ensure independence including setting fees in advance and utilizing analysts who must abide by CFA Institute Code of Ethics Code of Ethics can refer to:
Complete information about this company is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes. Investors are advised to read disclosures carefully before trading in the equities of any enrolled company. Anyone interested in receiving alerts regarding Chemokine research should email contact@investrend.com and distribution@fundamentalresearchcorp.com with "CTI" in the subject line. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion